Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Matthew Bannon

All right. Welcome back to the 44th Annual JPMorgan Healthcare Conference. My name is Matt Bannon, and I’m a banker here at JPM. I am very pleased to be introducing our final presenting company of the day, Exelixis. And presenting on behalf of the company, we’ll have President and CEO, Michael Morrissey.

Before I turn it over to Michael, I’ll remind folks that this is a Q&A session. So please raise your hand if you have a question or ask it through the online portal, and I’ll ask it on your behalf.

So without further ado, Michael?

Michael Morrissey
CEO, President & Director

All right. Fantastic. Thank you, and good evening, everybody. Thanks for hanging in there for one last session. I’ve been talking since 7:30 this morning. Meeting has been great, and I want to thank the JPMorgan team for the invitation and for the great, full packed schedule of one-on-one meetings. It’s just a great day, great way to start the year. And we’re excited to be able to tell you a little bit about Exelixis, where we’ve been in ’25 and where we’re going in 2026. So I’m going to follow my directions here with the pointer.

Okay. So before I begin, I’ll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business, first. Second, we have — we’re going to be speaking to preliminary financial results and 2026 guidance today. Please note that the preliminary financial results were generated as of January 11 of this year, and we will have — and are unaudited, and we’ll have a full review of the final